Home

Terumo Corp (TRUMF)

18.98
+2.54 (15.46%)
OP · Last Trade: Sep 10th, 3:06 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analystbenzinga.com
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Via Benzinga · January 23, 2024